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LoS Medicine was launched at a 
time of unprecedented concern 
about the inﬂ  uence of hidden 
competing interests on the medical 
literature. As a new journal, we had the 
opportunity to help create “the fully 
transparent world that is desirable” 
[1]. What are we doing to promote 
transparency, and is our strategy going 
far enough?
We ask all authors and reviewers 
to declare any competing interests—
ﬁ  nancial, personal, and professional 
[2]—and authors’ declarations are 
included with all published articles. 
We reject articles when we believe 
that authors’ competing interests have 
compromised their work; for research 
articles, this means compromised in 
either the conduct of a study or its 
interpretation. When we are concerned 
that reviewers’ competing interests may 
prevent them from giving an unbiased 
assessment, we ﬁ  nd alternative 
reviewers. And, as recommended 
by the International Committee of 
Medical Journal Editors [3], we decline 
to publish studies when the sponsor 
controls the decision on publication. 
Our main strategy for managing 
competing interests is disclosure. 
Financial relationships between 
industry, researchers, and academic 
institutions are widespread [4], and 
disclosing these competing interests is 
a crucial step in helping to protect the 
public and the reputation of authors 
and of PLoS Medicine. Disclosure also 
matters because there is increasing 
evidence that authors’ competing 
interests have a strong inﬂ  uence 
on their conclusions. For example, 
review articles looking at the scientiﬁ  c 
evidence on the health effects of 
passive smoking have reached different 
conclusions; a study of these review 
articles found that the only factor 
associated with the conclusion that 
passive smoking was harmless was 
whether an author was afﬁ  liated with 
the tobacco industry [5]. A study of 
159 randomized clinical trials found a 
signiﬁ  cant association between authors’ 
ﬁ  nancial competing interests and 
their favorable conclusions about an 
experimental intervention [6]. 
We cannot rely entirely on peer 
review to detect bias in the conclusions 
of an article, because although peer 
review may help to uncover some types 
of bias, such as bias in the study design, 
it cannot detect other types, such as 
bias in the study’s conduct. Because 
a competing interests statement 
accompanies every article published in 
PLoS Medicine, readers can take these 
interests into account when they assess 
a paper themselves. The reality is that 
readers are wary of competing interests. 
In one study, readers were randomly 
sent the same paper with or without 
the authors having disclosed a ﬁ  nancial 
competing interest [7]. Readers scored 
the paper with the competing interest 
signiﬁ  cantly lower on all ﬁ  ve measures: 
interest, importance, relevance, validity, 
and believability of the study.
Our policy of asking authors to 
disclose their competing interests is 
not, of course, foolproof. The Center 
for Science in the Public Interest 
recently examined 163 articles in 
four scientiﬁ  c journals and identiﬁ  ed 
at least 13 articles for which authors 
did not disclose relevant conﬂ  icts 
of interest that should have been 
disclosed according to the journals’ 
policies [8]. Bero and colleagues 
compared the statement of competing 
interests of the authors of a 2003 
BMJ paper on the health effects of 
secondhand smoke with internal 
tobacco industry documents describing 
ﬁ  nancial ties between the industry 
and the authors [9]. Although the 
authors met the BMJ ’s requirements 
for ﬁ  nancial disclosure, the disclosure 
did not provide readers with a full 
picture of the industry’s long-standing 
involvement with the authors.  
Should we as journal editors be 
investigating authors’ ties for ourselves? 
We do not have the resources to do so, 
and agree with Bero and colleagues 
that “an elaborate policing operation 
is not feasible or necessarily desirable” 
[9]. But in this particular case, say the 
authors, a quick search of the tobacco 
documents that are freely available 
online (e.g., at http:⁄⁄www.legacy.
library.ucsf.edu or http:⁄⁄www.bat.
library.ucsf.edu) would have been 
revealing. Maybe we are heading 
towards an era when such searches 
become more common—perhaps 
initially by randomly selecting papers 
for investigation.
At last year’s Council of Science 
Editors retreat on competing interests, 
editors came up with a list of questions 
to think about when formulating a 
journal’s competing interests policy 
(Table S1). Some are straightforward. 
Should editors declare their own 
competing interests? We think so (and 
have declared ours at http:⁄⁄medicine.
plosjournals.org/perlserv/?request=get-
static&name=editors_interests). Others 
are more complex. When editors 
discover that a published author failed 
to declare a signiﬁ  cant competing 
interest, what should they do? Should 
they impose sanctions on the author? 
Should they publish a correction or 
even retract the paper?
To help us answer such questions, 
and to advise us on individual cases 
for which we are concerned about 
competing interests or broader ethical 
questions, we have appointed an 
external advisory group. The group 
(Table S2) has expertise in clinical 
medicine, medical editing, research, 
health policy, law, and bioethics, and 
includes a lay member. In addition, 
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an internal committee at PLoS meets 
monthly to consider competing 
interests across the organization. We 
are taking this issue seriously, because 
we recognize that journals are seen as 
the gatekeepers of published research. 
We welcome your feedback on how we 
are doing at protecting the probity of 
our content.  
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Table S1. Competing Interests Policies: 
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